Mesenchymal stem cells: a new therapeutic tool for AKI (original) (raw)

Nature Reviews Nephrology volume 6, pages 179–183 (2010)Cite this article

Subjects

Abstract

Acute kidney injury (AKI) is a common clinical complication, associated with poor outcomes and the development of chronic kidney disease. Despite major advances in the understanding of its pathophysiology, available therapies for AKI are only supportive; therefore, adequate functional recovery from AKI must predominantly rely on the kidney's own reparative ability. An extensive body of preclinical data from our own and from other laboratories has shown that administration of adult multipotent marrow stromal cells (commonly referred to as mesenchymal stem cells [MSCs]), effectively ameliorates experimental AKI by exerting paracrine renoprotective effects and by stimulating tissue repair. Based on these findings, a clinical trial has been conducted to investigate the safety and efficacy of MSCs administered to open-heart surgery patients who are at high risk of postoperative AKI. In this Perspectives article, we discuss some of the early data from this trial and describe potential applications for stem cell therapies in other fields of nephrology.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$189.00 per year

only $15.75 per issue

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

References

  1. Waikar, S. S., Liu, K. D. & Chertow, G. M. Diagnosis, epidemiology and outcomes of acute kidney injury. Clin. J. Am. Soc. Nephrol. 3, 844–861 (2008).
    Article Google Scholar
  2. Macedo, E., Bouchard, J. & Mehta, R. L. Renal recovery following acute kidney injury. Curr. Opin. Crit. Care 14, 660–665 (2008).
    Article Google Scholar
  3. Kelly, K. J. & Molitoris, B. A. Acute renal failure in the new millennium: time to consider combination therapy. Semin. Nephrol. 20, 4–19 (2000).
    CAS PubMed Google Scholar
  4. Chertow, G. M. On the design and analysis of multicenter trials in acute renal failure. Am. J. Kidney Dis. 30 (Suppl. 4), S96–S101 (1997).
    Article CAS Google Scholar
  5. Hirschberg, R. et al. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int. 55, 2423–2432 (1999).
    Article CAS Google Scholar
  6. Waikar, S. S. & Bonventre, J. V. Creatinine kinetics and the definition of acute kidney injury. J. Am. Soc. Nephrol. 20, 672–679 (2009).
    Article CAS Google Scholar
  7. Coca, S. G., Yalavarthy, R., Concato, J. & Parikh, C. R. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int. 73, 1008–1016 (2008).
    Article CAS Google Scholar
  8. Vaidya, V. S. et al. A rapid urine test for early detection of kidney injury. Kidney Int. 76, 108–114 (2009).
    Article CAS Google Scholar
  9. Gnecchi, M., Zhang, Z., Ni, A. & Dzau, V. J. Paracrine mechanisms in adult stem cell signaling and therapy. Circ. Res. 103, 1204–1219 (2008).
    Article CAS Google Scholar
  10. Phinney, D. G. & Prockop, D. J. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair--current views. Stem Cells 25, 2896–2902 (2007).
    Article Google Scholar
  11. Tögel, F., Zhang, P., Hu, Z. & Westenfelder, C. VEGF is a mediator of the renoprotective effects of multipotent marrow stromal cells in acute kidney injury. J. Cell. Mol. Med. 13, 2109–2114 (2009).
    Article Google Scholar
  12. Tögel, F. et al. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am. J. Physiol. Renal Physiol. 292, F1626–F1635 (2007).
    Article Google Scholar
  13. Morigi, M. et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J. Am. Soc. Nephrol. 15, 1794–1804 (2004).
    Article Google Scholar
  14. Tögel, F. et al. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am. J. Physiol. Renal Physiol. 289, F31–F42 (2005).
    Article Google Scholar
  15. Lange, C. et al. Administered mesenchymal stem cells enhance recovery from ischemia/reperfusion-induced acute renal failure in rats. Kidney Int. 68, 1613–1617 (2005).
    Article Google Scholar
  16. Tögel, F. et al. Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury. Stem Cells Dev. 18, 475–485 (2009).
    Article Google Scholar
  17. Duffield, J. S. et al. Restoration of tubular epithelial cells during repair of the postischemic kidney occurs independently of bone marrow-derived stem cells. J. Clin. Invest. 115, 1743–1755 (2005).
    Article CAS Google Scholar
  18. Bruno, S. et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J. Am. Soc. Nephrol. 20, 1053–1067 (2009).
    Article CAS Google Scholar
  19. Imberti, B. et al. Insulin-like growth factor-1 sustains stem cell mediated renal repair. J. Am. Soc. Nephrol. 18, 2921–2928 (2007).
    Article CAS Google Scholar
  20. Sheridan, A. M. & Bonventre, J. V. Cell biology and molecular mechanisms of injury in ischemic acute renal failure. Curr. Opin. Nephrol. Hypertens. 9, 427–434 (2000).
    Article CAS Google Scholar
  21. Giordano, A., Galderisi, U. & Marino, I. R. From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J. Cell. Physiol. 211, 27–35 (2007).
    Article CAS Google Scholar
  22. US Clinical trials website [online], (2009).
  23. US Clinical Trials Allogeneic Multipotent Stromal Cell Treatment for Acute Kidney Injury Following Cardiac Surgery [online], (2009).
  24. Gooch, A. et al. Initial report on a phase I clinical trial: prevention and treatment of post-operative acute kidney injury with allogeneic mesenchymal stem cells in patients who require on-pump cardiac surgery. Cellular Therapy and Transplantation [online], (2008).
  25. Koç, O. N. et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J. Clin. Oncol. 18, 307–316 (2000).
    Article Google Scholar
  26. Le Blanc, K. et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371, 1579–1586 (2008).
    Article CAS Google Scholar

Download references

Acknowledgements

The authors' research discussed in this Perspectives article was in part supported by funds from the Merit Review program of the Veterans Administration, Washington, DC, the NIH, the American Heart Association, the National Kidney Foundation, the Western Institute for Biomedical Research, and Allocure, Inc. The human MSCs that were administered to study subjects in the phase I clinical trial were prepared in the cGMP Cell Therapy Facility of the University of Utah, UT, USA. The outstanding skills of the principal investigators (J. Doty, Intermountain Medical Center, Murray, UT; D. Affleck, St. Mark's Hospital, Salt Lake City, UT), co-principal investigators (B. Horne and B. Muhlestein, Intermountain Medical Center; S. Karwande and G. Schorlemmer, St. Mark's Hospital), and study nurses (J. Flores, Intermountain Medical Center; A. Creer, St. Mark's Hospital) are gratefully acknowledged. The contributions of the members of the Data Safety and Monitoring Board for the phase I trial discussed in this article, C. Kablitz, G. R. Reiss, and S. Beddhu, are also greatly appreciated. Finally, the excellent bench work of Z. Hu and P. Zhang for the conduct of the described preclinical studies is acknowledged, and the regulatory contributions of A. Gooch were invaluable for the conduct of the described clinical trial.

Author information

Authors and Affiliations

  1. Department of Medicine, Weill Cornell College of Medicine and New York Presbyterian Hospital, 1300 York Avenue, New York, 10021, NY, USA
    Florian E. Tögel
  2. Division of Nephrology, University of Utah and VA Medical Centers, 500 Foothill Boulevard, Salt Lake City, 84148, UT, USA
    Christof Westenfelder

Authors

  1. Florian E. Tögel
  2. Christof Westenfelder

Corresponding author

Correspondence toChristof Westenfelder.

Ethics declarations

Competing interests

C. Westenfelder has acted as a consultant, received grant/research support from and is a patent holder/applicant for Allocure. F.E. Tögel declares no competing interests.

Rights and permissions

About this article

Cite this article

Tögel, F., Westenfelder, C. Mesenchymal stem cells: a new therapeutic tool for AKI.Nat Rev Nephrol 6, 179–183 (2010). https://doi.org/10.1038/nrneph.2009.229

Download citation

This article is cited by